文献速递中毒与环境急症儿科与产科急症

儿童患者单物质暴露相关癫痫发作:15年回顾性研究

Seizures associated with single substance exposures in pediatric patients: a 15-year retrospective study.
PubMed 文献 · Clin Toxicol (Phila) · 2025-06-30
一句话结论美国中毒中心15年数据显示,儿童单物质暴露相关癫痫发作病例和发作率均上升,主要驱动物质为苯海拉明和安非他酮,近半数需入住重症监护病房。

该研究基于美国国家中毒数据系统2009至2023年数据,纳入20岁以下因单物质暴露出现癫痫发作(单次发作、多次/离散发作或癫痫持续状态)的患儿。共识别30,985例,其中癫痫持续状态1,712例;报告病例从2009年1,418例增至2023年2,749例,发作率从88/10万暴露增至237/10万暴露。13-19岁占66.9%,0-5岁占24.0%,6-12岁占9.1%。苯海拉明和安非他酮是主要贡献物质,苯海拉明相关发作从2009年85例增至2023年404例,安非他酮从2013年162例增至2023年431例。中度效应占41.9%,重度效应占35.8%,47.8%需入住重症监护病房。

要点

  • 2009至2023年美国中毒中心儿童单物质暴露相关癫痫发作报告从1,418例增至2,749例,发作率从88/10万暴露升至237/10万暴露。
  • 13-19岁青少年占病例66.9%,0-5岁占24.0%,6-12岁占9.1%,女性病例增加明显。
  • 苯海拉明和安非他酮是主要贡献物质:苯海拉明相关发作从2009年85例增至2023年404例,安非他酮从2013年162例增至2023年431例。
  • 30,985例中1,712例为癫痫持续状态;中度效应占41.9%,重度效应占35.8%,47.8%需入住重症监护病房。

适用人群与场景

  • 20岁以下儿童患者,因单物质暴露出现癫痫发作(单次发作、多次/离散发作或癫痫持续状态)并报告至美国国家中毒数据系统,2009至2023年。

研究设计与关键结果

  • 回顾性研究纳入美国国家中毒数据系统2009至2023年20岁以下单物质暴露相关癫痫发作患者30,985例,其中癫痫持续状态1,712例。
  • 报告病例从2009年1,418例增至2023年2,749例,发作率从88/10万暴露增至237/10万暴露。
  • 年龄分布:13-19岁占66.9%,0-5岁占24.0%,6-12岁占9.1%。
  • 苯海拉明相关发作从2009年85例增至2023年404例;安非他酮相关病例从2013年162例增至2023年431例。
  • 中度效应占41.9%,重度效应占35.8%,47.8%需入住重症监护病房。

证据类型、等级与局限

  • 证据类型:回顾性研究,基于美国国家中毒数据系统2009至2023年数据。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,儿童单物质暴露相关癫痫发作呈上升趋势,主要由苯海拉明和安非他酮驱动,需采取针对性预防策略以减轻中毒暴露负担并保障儿童健康。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

INTRODUCTION: This study aims to evaluate the trends, demographics, outcomes, and substances associated with single-substance exposures associated with in seizures in pediatric patients over 15 years.

METHODS: This retrospective study of the National Poison Data System® was conducted from 2009 to 2023, including pediatric patients (<20 years) who experienced seizures as a clinical effect associated with single-substance exposures. Cases with single seizures, multi/discrete seizures, or status epilepticus were included. Trends in annual frequency, seizure rates (per 100,000 exposures), and substances associated with seizures were examined.

RESULTS: Thirty thousand nine hundred and eighty-five patients with single-substance exposures associated with seizures were identified, including 1,712 cases of status epilepticus. Reports to poison centers saw an increase in cases with seizures from 1,418 in 2009 to 2,749 in 2023. The seizure rate increased from 88 to 237 per 100,000 exposures. Patients aged 13-19 years accounted for the majority of cases (66.9%), followed by aged 0-5 years (24.0%) and 6-12 years (9.1%). Diphenhydramine and bupropion were the leading contributors, with diphenhydramine-related seizures increasing from 85 in 2009 to 404 in 2023 and bupropion cases rising from 162 in 2013 to 431 in 2023. Moderate and major effects were reported in 41.9% and 35.8% of cases, respectively, with nearly half (47.8%) requiring admission to critical care units.

DISCUSSION: The current study shows an increase in substance-related pediatric seizures, particularly among adolescents and females. The significant need for critical care in nearly half of these cases shows the severity and potential long-term impact of these exposures.

CONCLUSIONS: Pediatric seizures associated with single-substance exposures are on the rise, driven primarily by diphenhydramine and bupropion. This trend highlights the need for targeted prevention strategies to reduce the burden of toxic exposures and safeguard the well-being of pediatric populations.

来源:Clin Toxicol (Phila),查看原文。版权归原作者所有。

参考来源

  1. Chang CM, Holstege CP, McDonald CT, et al. Seizures associated with single substance exposures in pediatric patients: a 15-year retrospective study. Clin Toxicol (Phila). 2025. PMID: 40587100. doi:10.1080/15563650.2025.2519321

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。